Rutgers Cancer Institute of New Jersey: Assessing Data Integrity in Times of COVID-19
June 05, 2020
June 05, 2020
NEW BRUNSWICK, New Jersey, June 5 -- Rutgers Cancer Institute of New Jersey issued the following news:
As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial. Weichung 'Joe' Shih, PhD, director of the Biometrics Shared Resource at Rutgers Cancer Instit . . .
As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial. Weichung 'Joe' Shih, PhD, director of the Biometrics Shared Resource at Rutgers Cancer Instit . . .